For more information on the convention or to register, click here.
About NVX-CoV2373NVX-CoV2373 is a candidate vaccine designed from the genetic series of SARS-CoV-2, the virus responsible for the COVID-19 disease. NVX-CoV2373 was created using Novavax’s generation of recombinant nanoparticles to generate an antigen derived from the coronavirus spike protein (S) and comprises Novavax’s proprietary saponin-based Matrix-M ™ adjuvant for immune reaction and stimulating levels maxima of neutralizing antibodies. NVX-CoV2373 comprises purified protein antigens and cannot replicate or cause COVID-19. In preclinical trials, NVX-CoV2373 has demonstrated an indication of antibodies that block the binding of the spike protein to targeted receptors throughout the virus, a critical facet for effective protection of the vaccine. In its Phase 1 portion of its Phase 1/2 clinical trial, NVX-CoV2373 was sometimes well tolerated and elicited physically powerful antibody reactions that were numerically staggering to those seen in human convalescent sera. NVX-CoV2373 is also being evaluated in a UK phase 3 trial and two ongoing phase 2 studies, which began in August; a phase 2b trial in South Africa and a phase 1/2 continuation in the United States and Australia. Novavax has secured a $ 2 billion investment for its global coronavirus vaccine program, adding up to $ 388 million in investment from the Coalition for Innovations in Epidemic Preparedness (CEPI).
Contacts: Investors Silvia Taylor and Erika Trahanir@novavax. com240-268-2022